Broadening this approach beyond EGFR-mutant lung cancer requires robust methods for estimating ctDNA content, such as the calculation of ctDNA tumor fraction (TF), an algorithmic method that can provide information on ctDNA content even without the detection of pathogenic variants [4,7]. The gene discussed is EGFR; the disease is lung cancer.